Activated charcoal 100mg / Magnesium hydroxide 100mg tablets
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Activated charcoal + Magnesium hydroxide
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 6 · Randomised trials: 3 · 1989–2026
Showing the 50 most relevant studies, sorted by most relevant.
Lotte C. G. Hoegberg, Greene Shepherd, David M. Wood, et al.
Clinical Toxicology, 2021
- Charcoal
- Drug Overdose
- Acetaminophen
María Alejandra Décima, Simone Marzeddu, Margherita Barchiesi, et al.
Sustainability, 2021
Hadi Bahmani, Davood Mostofinejad
European Journal of Environmental and Civil Engineering, 2023
B. Coffin, Claude Bortolloti, O. Bourgeois, et al.
Clinics and research in hepatology and gastroenterology, 2011
Kimberly O. Cameron, Daniel W. Kung, Amit S. Kalgutkar, et al.
Journal of Medicinal Chemistry, 2016
- Adsorption
- Diabetic Nephropathies
- Dogs
Kundu S, Khandaker T, Anik MAM, et al.
2024
The increasing level of atmospheric CO2 requires the urgent development of effective capture technologies. This comprehensive review thoroughly examines various methods for the synthesis of carbon materials, modification techniques for converting biomass feedstock into carbon materials and pivotal factors impacting their properties. The novel aspect of this review is its in-depth comparison of how these modifications specifically affect the pore structure and surface area together with the exploration of the mechanism underlying the enhancement of CO2 adsorption performance. Additionally, this review addresses research gaps and provides recommendations for future studies concerning the advantages and drawbacks of CO2 adsorbents and their prospects for commercialization and economic feasibility. This article revealed that among the various strategies, template carbonization offers a viable option for providing control of the material pore diameter and structure without additional modification treatments. Optimizing the pore structure of activated carbons, particularly those activated with agents such as KOH and ZnCl2, together with synthesizing hybrid activated carbons using multiple activating agents, is crucial for enhancing their CO2 capture performance. Cost-benefit analysis suggests that biomass-derived activated carbons can significantly meet the escalating demand for CO2 capture materials, offering economic advantages and supporting sustainable waste management.
Abstract licence: CC BY-NC
A. Botha, C.A. Strydom
Hydrometallurgy, 2001
Ikmal Hakem Aziz, Mohd Mustafa Al Bakri Abdullah, Mohd Arif Anuar Mohd Salleh, et al.
Materials, 2022
M. Yadav, Narendra Pratap Singh, Anuj Kumar
Journal of Materials Science: Materials in Electronics, 2018
F. Bruns, D. Riesenbeck, R. Muecke, et al.
Journal of Clinical Oncology, 2007
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.